Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T21:48:20.522Z.
Calculation as of: 2026-10-06T21:48:20.522Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69c6abe1898d62982c9f5472fcc208679ef9964d1dbc89e7ebe68f1e3eabf120
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2020-05-12.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
EBITDA YIELD AVG TTM
N/A
EBITDA YIELD AVG 3Y
N/A
EBITDA YIELD AVG 5Y
N/A
EBITDA YIELD AVG 10Y
N/A
EBITDA YIELD AVG 15Y
N/A
EBITDA YIELD AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$143.84M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.62M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | $143.60M | N/A | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $143.84M | N/A | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $143.10M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $146.27M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $146.28M | N/A | 1.29% | 1.28% | 1.28% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | N/A | N/A | N/A | N/A |
| Sutro Biopharma, Inc. (STRO)vs › | $139.84M | N/A | N/A | N/A | N/A |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $139.04M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA YIELD |
|---|---|
| 2020-05-12 | 2.17% |
| 2020-05-11 | 2.12% |
| 2020-05-08 | 2.17% |
| 2020-05-07 | 2.06% |
| 2020-05-06 | 2.03% |
| 2020-05-05 | 1.98% |
| 2020-05-04 | 2.07% |
| 2020-05-01 | 2.22% |
| 2020-04-30 | 2.18% |
| 2020-04-29 | 2.20% |
| 2020-04-28 | 2.23% |
| 2020-04-27 | 2.23% |
| 2020-04-24 | 2.23% |
| 2020-04-23 | 2.29% |
| 2020-04-22 | 2.34% |
| 2020-04-21 | 2.38% |
| 2020-04-20 | 2.39% |
| 2020-04-17 | 2.28% |
| 2020-04-16 | 2.25% |
| 2020-04-15 | 2.23% |
| 2020-04-14 | 2.22% |
| 2020-04-13 | 2.33% |
| 2020-04-09 | 2.40% |
| 2020-04-08 | 2.25% |
| 2020-04-07 | 2.30% |
| 2020-04-06 | 2.44% |
| 2020-04-03 | 2.32% |
| 2020-04-02 | 2.23% |
| 2020-04-01 | 2.20% |
| 2020-03-31 | 2.33% |
| 2020-03-30 | 2.49% |
| 2020-03-27 | 2.45% |
| 2020-03-26 | 2.44% |
| 2020-03-25 | 2.38% |
| 2020-03-24 | 2.23% |
| 2020-03-23 | 2.56% |
| 2020-03-20 | 2.30% |